TNDM earnings face scrutiny as transition to pay-as-you-go insulin delivery impacts near-term margins and revenue growth.
Tandem Diabetes Care reported a 12% year-over-year revenue increase to $245 million in Q2, but gross margins fell 300 basis points to 52% due to its new pay-as-you-go insulin delivery model. The shift, aimed at long-term customer retention, has raised near-term cost concerns among analysts.
Prior to the model change, Tandem posted gross margins of 55% in Q1 and 56% in the same quarter last year. Consensus estimates had projected 54% margins for Q2, highlighting the miss. The company expects the transition to stabilize by 2025.
Shares of TNDM fell 8% in after-hours trading following the earnings release, reflecting investor unease over margin compression.